BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets SAN CARLOS, Calif. & REDWOOD CITY, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: […]